The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on stand out poster presentations as most likely to influence day-to-day chronic lymphocytic leukemia (CLL) management, highlighting those that described patterns of resistance mutations in patients treated with targeted therapy, particularly BTK inhibitors. Prof. Ferrajoli notes that recurring themes included geographic approaches to CLL and the use of artificial intelligence (AI) to facilitate shared decision making, with patients valuing treatment-free periods more than expected. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
